Who are AMX0035's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NeuroAiD, Butylphthalide Soft Capsules, Xaliproden (SR57746A), Butylphthalide soft capsule, Edaravone Dexborneol Sequential Therapy, NXY-059.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amx0035.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AMX0035 — Competitive Intelligence Brief

AMX0035 (AMX0035) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuroprotective agent; combination therapy. Area: Neurology.

phase 3 Neuroprotective agent; combination therapy ER stress pathway, mitochondrial stability, neuroinflammation Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AMX0035 (AMX0035) — Amylyx Pharmaceuticals Inc.. AMX0035 is a fixed-dose combination of sodium phenylbutyrate and taurursodiol that reduces neuroinflammation and protects motor neurons by stabilizing mitochondrial function and reducing ER stress.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AMX0035 TARGET	AMX0035	Amylyx Pharmaceuticals Inc.	phase 3	Neuroprotective agent; combination therapy	ER stress pathway, mitochondrial stability, neuroinflammation
NeuroAiD	NeuroAiD	CHIMES Society	marketed	Herbal neuroprotective agent
Butylphthalide Soft Capsules	Butylphthalide Soft Capsules	Peking Union Medical College Hospital	marketed	Neuroprotective agent
Xaliproden (SR57746A)	Xaliproden (SR57746A)	Sanofi	phase 3	Neuroprotective agent	NMDA receptor
Butylphthalide soft capsule	Butylphthalide soft capsule	Capital Medical University	phase 3	Neuroprotective agent	Mitochondrial function modulator (non-specific)
Edaravone Dexborneol Sequential Therapy	Edaravone Dexborneol Sequential Therapy	Simcere Pharmaceutical Co., Ltd	phase 3	Neuroprotective agent combination
NXY-059	NXY-059	AstraZeneca	phase 3	Free radical scavenger / Neuroprotective agent	Reactive oxygen species (ROS) / Free radicals

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuroprotective agent; combination therapy class)

Amylyx Pharmaceuticals Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMX0035 — Competitive Intelligence Brief. https://druglandscape.com/ci/amx0035. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab